Disease Roundup: Four Gene-Editing Candidates in...
Sep. 20, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Novartis
Main (CRISPR) focus: Treatment of genetic blood diseases and cancer
Company stage: Clinical
Diseases: Sickle cell disease, cancer
Genome editing tool: CRISPR-Cas9, Zinc-finger nuclease, Neuro-developmental disorders
Funding stage: Public (NASDAQ:NVS)
Location: Cambridge, MA, USA (Headquarters), Basel, Switzerland
Website: https://www.novartis.com/
Pipeline: https://www.novartis.com/our-science/novartis-global-pipeline
Partners: Intellia Therapeutics, Sangamo Therapeutics
Novartis is global big pharma company. The company is mainly involved in the therapeutic development of gene-editing technologies through a partnership with Intellia Therapeutics. The two companies are co-developing a programme for the treatment of sickle cell disease, which is currently being tested in early clinical trials. The companies are also developing multiple undisclosed pre-clinical assets.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
